Godet Cendrine, Philippe Bruno, Laurent François, Cadranel Jacques
Department of Infectious Diseases, CHU la Milétrie, Poitiers, France.
Respiration. 2014;88(2):162-74. doi: 10.1159/000362674. Epub 2014 Jun 17.
Chronic pulmonary aspergillosis (CPA) affects individuals with non-systemic or mildly systemic immunodepression or altered pulmonary integrity due to underlying disease. It has been reported with a variety of clinical and radiological patterns. The condition should be distinguished from simple aspergilloma and allergic bronchopulmonary aspergillosis as well as invasive aspergillosis in severely immunocompromised patients. CPA generally requires long-term antifungal treatment and surgery may be considered. Life-threatening haemoptysis may be prevented by bronchial arteriography with embolisation. However, currently there are no documented treatment recommendations for CPA. This review provides an up-to-date practical overview of this condition, including a comprehensive update on diagnosis and management.
慢性肺曲霉病（CPA）影响非系统性或轻度系统性免疫抑制个体，或因基础疾病导致肺完整性改变的个体。它有多种临床和影像学表现。该疾病应与单纯曲菌球、变应性支气管肺曲霉病以及严重免疫功能低下患者的侵袭性曲霉病相鉴别。CPA通常需要长期抗真菌治疗，也可考虑手术治疗。支气管动脉造影及栓塞术可预防危及生命的咯血。然而，目前尚无关于CPA的书面治疗建议。本综述提供了关于该疾病的最新实用概述，包括诊断和管理的全面更新。
